Chikungunya’s 2025 surge sparks urgent research response

The world is facing the largest recorded global spread of chikungunya virus (CHIKV), with outbreaks this year reported in more than 119 countries

and

extending into temperate zones of Europe. The mosquito-borne virus, long regarded as a tropical health concern, has surged on the Indian Ocean isl

and

s of Réunion, Mayotte

and

Mauritius. Autochthonous (locally acquired) transmission has also been confirmed in France’s Gr

and

Est

and

south-eastern regions. The World Health Organization (WHO) estimates that 5.6 billion people may be at risk of exposure in 2025.

Exp

and

ing threat

Chikungunya belongs to the alphavirus genus

and

is primarily transmitted by Aedes aegypti

and

Aedes albopictus mosquitoes. Symptoms typically include sudden onset of high fever, rash

and

severe joint pain, often accompanied by muscle aches

and

headache. Although the disease is rarely fatal, it can leave patients with chronic pain

and

disability lasting months or years. Vulnerable groups such as infants, older adults

and

those with underlying conditions are particularly affected.

Chikungunya belongs to the alphavirus genus

and

is primarily transmitted by Aedes aegypti

and

Aedes albopictus mosquitoes.

This year’s expansion of transmission is being attributed to a convergence of factors. Climate change has enabled Aedes mosquitoes to colonise new regions, while rapid urbanisation provides ideal breeding environments. International travel has accelerated the spread of the virus to non-endemic regions

and

the absence of herd immunity following several years without large-scale outbreaks has left populations exposed. Surveillance challenges

and

inconsistent access to diagnostics have further delayed early detection, allowing the virus to establish footholds in new areas.

A recent Lancet commentary described chikungunya’s return to Europe as “a turning point for the global arboviral l

and

scape”, according to Zumla et al. published earlier this year. The World Health Organization has also raised concern over the pace of spread, warning in its June 2025 update that the virus has reached regions not previously considered at risk.

The transmission cycle of chikungunya virus. The virus spreads primarily via

Aedes aegypti

and

Aedes albopictus

mosquitoes. Infected mosquitoes pass the virus to humans through bites, while infected humans can in turn infect new mosquitoes, sustaining the cycle. Image credit:

CDC

[/caption]

Limited treatment options

There is still no licensed antiviral treatment for CHIKV. Clinical management remains supportive, focused on relieving fever

and

inflammation to reduce patient discomfort. This therapeutic gap is particularly problematic in low-resource settings where health systems are already burdened by dengue

and

malaria.

The vaccine pipeline, however, has begun to bear fruit. Two c

and

idates have reached the market in recent years:

• IXCHIQ, a live-attenuated vaccine, is approved for adults, though with restrictions for older populations due to safety considerations.
• VIMKUNYA, a virus-like particle vaccine, is authorised as a single-dose injection for individuals aged 12

  and

  above.

While these vaccines mark important milestones, global access remains limited. Regulatory timelines, cost considerations

and

supply constraints continue to leave much of the world reliant on vector control, community awareness campaigns

and

case surveillance as the primary tools of defence.

Research response gains momentum

The scale of the 2025 outbreak has galvanised both academic

and

industry-led research. Efforts include testing vaccine durability

and

cross-protection against emerging CHIKV variants. Researchers are also screening compound libraries for antiviral activity, while new diagnostics are being designed to distinguish chikungunya from co-circulating viruses such as dengue

and

Zika.

Laboratory reagents have proven central to this accelerated response. Recombinant viral proteins

and

antibodies are allowing researchers to model immune responses, evaluate neutralising titres

and

design next-generation diagnostic assays.

To address the ongoing CHIKV outbreak, Sino Biological swiftly initiated the development of recombinant E1

and

E2 proteins, together with specific antibodies. These reagents are providing crucial support for researchers working on vaccine development, antiviral therapies

and

immunodiagnostic assay creation.

The company also supplies key tools including the recombinant CHIKV E2 glycoprotein, complementary DNA (cDNA) clones

and

specialised antibodies for enzyme-linked immunosorbent assay (ELISA)

and

lateral flow assays (LFA). All are produced under strict quality controls to ensure reliability.

Detection of recombinant CHIKV-E2, ZIKV-E

and

DENV-E proteins at serial dilutions using peptide aptamers B2

and

B3. Image credit: Liu et al. 2023

[/caption]

A number of peer-reviewed publications have employed Sino Biological proteins

and

antibodies. Examples include:

• Liu

  and

  Gu employed the recombinant CHIKV E2 protein (40440-V08B) in an aptamer-based time-resolved fluoroimmunoassay, demonstrating peptide binding affinity

  and

  specificity to E2 antigens.
• Tamburini et al. investigated viral antigen acquisition in lymphatic endothelial cells (LEC), blood endothelial cells (BEC)

  and

  fibroblastic reticular cells (FRC) in mice infected with recombinant CHIKV E2 conjugated to AlexaFluor-488. They reported that both LECs

  and

  a subset of FRCs acquired the viral protein during the treatment window.
• Kim et al. used recombinant E2 protein pre-coated ELISA plates to compare immune responses, showing that glycan-mutant envelope proteins induced lower humoral responses than the full-length E protein.

By supplying validated reagents for these investigations, Sino Biological has enabled scientists to accelerate discovery at a time when speed

and

reliability are crucial.

Measurement of total IgG levels against CHIKV-E2 in sera from individual mice using ELISA with recombinant CHIKV-E2 protein pre-coated plates.

Image credit: Kim et al. 2024

[/caption]

Industry

and

academic partnerships

The outbreak has also highlighted the growing importance of collaboration between biotechnology companies

and

academic researchers. Reliable reagents shorten experimental timelines

and

reduce variability, accelerating the transition from early discovery to translational research. As chikungunya spreads into regions previously unprepared for arboviral outbreaks, the ability to generate reproducible, high-quality data quickly has become a critical part of the response.

From outbreak to action

The chikungunya outbreak of 2025 is a reminder that arboviruses do not respect geographical boundaries. As WHO

and

national health authorities work to strengthen vector control

and

surveillance, researchers are racing to fill the therapeutic

and

diagnostic gaps.

For drug discovery scientists, the outbreak represents both a challenge

and

an opportunity. The urgent need for antivirals, widely available vaccines

and

scalable diagnostics is driving innovation across multiple fronts. Partnerships between public health agencies, academic groups

and

industry providers such as Sino Biological are proving essential to this effort. Further details of Sino Biological’s portfolio of recombinant antigens

and

antibodies for chikungunya research are available on the company’s website.

The global health community has learned difficult lessons from dengue

and

Zika. Chikungunya is now firmly established as a worldwide threat, making it a priority to translate scientific advances into accessible interventions before the next epidemic wave arrives.

References

• Adam A, et al. A safe insect-based chikungunya fever vaccine affords rapid

  and

  durable protection in cynomolgus macaques. NPJ Vaccines. 2024;9:65.
• Centers for Disease Control

  and

  Prevention. Areas at risk for chikungunya [Internet]. Atlanta (GA): CDC; 2025 [cited 2025 Aug 22]. Available from: https://www.cdc.gov/chikungunya/data-maps/index.html
• de Souza WM, Lecuit M, Weaver SC. Chikungunya virus

  and

  other emerging arthritogenic alphaviruses. Nat Rev Microbiol. 2025;23(7):401–15. doi:10.1038/s41579-025-01177-8.
• Doan TA, et al. Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection. NPJ Vaccines. 2024;9:112.
• European Centre for Disease Prevention

  and

  Control. Chikungunya virus disease worldwide overview. Stockholm: ECDC; 2025. Preprint.
• Frumence E, et al. Genomic insights into the re-emergence of chikungunya virus on Réunion Isl

  and

  , France, 2024 to 2025. Euro Surveill. 2025;30(12):240032.
• Kim K, et al. Immunogenicity analysis of chikungunya virus DNA vaccine based on mutated putative N-linked glycosylation sites of the envelope protein. Vaccines (Basel). 2024;12(5):842.
• Liu T, et al. Peptide aptamer-based time-resolved fluoroimmunoassay for CHIKV diagnosis. Virol J. 2023;20:189.
• Roiz D, Boussès P, Simard F, Paupy C, Fontenille D. Autochthonous Chikungunya transmission

  and

  extreme climate events in Southern France. PLoS Negl Trop Dis. 2015;9(6):e0003854.
• World Health Organization. Chikungunya epidemiology update – June 2025 [Internet]. Geneva: WHO; 2025 [cited 2025 Aug 22]. Available from: https://www.who.int/publications/m/item/chikungunya-epidemiology-update-june-2025
• World Health Organization raises concern about spread of mosquito-borne Chikungunya virus. Reuters [Internet]. 2025 Jul 22 [cited 2025 Aug 22]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/world-health-organization-raises-concern-about-spread-mosquito-borne-chikungunya-2025-07-22/
• What is the chikungunya virus, how are countries such as China battling it? Al Jazeera [Internet]. 2025 Aug 6 [cited 2025 Aug 22]. Available from: https://www.aljazeera.com/news/2025/8/6/what-is-the-chikungunya-virus-how-are-countries-such-as-china-battling-it
• Zumla A, Ntoumi F, Ippolito G, PANDORA-ID-NET Consortium. Chikungunya virus disease returns to Europe: a turning point for the global arboviral l

  and

  scape. Lancet. 2025;405(10332):345–7.